You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
|
|---|---|
| Published in |
Breast Cancer Research, November 2020
|
| DOI | 10.1186/s13058-020-01354-y |
| Pubmed ID | |
| Authors |
Ana C. Garrido-Castro, Cristina Saura, Romualdo Barroso-Sousa, Hao Guo, Eva Ciruelos, Begoña Bermejo, Joaquin Gavilá, Violeta Serra, Aleix Prat, Laia Paré, Pamela Céliz, Patricia Villagrasa, Yisheng Li, Jennifer Savoie, Zhan Xu, Carlos L. Arteaga, Ian E. Krop, David B. Solit, Gordon B. Mills, Lewis C. Cantley, Eric P. Winer, Nancy U. Lin, Jordi Rodon |
X Demographics
The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 5 | 45% |
| United States | 2 | 18% |
| Mexico | 1 | 9% |
| Unknown | 3 | 27% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 64% |
| Practitioners (doctors, other healthcare professionals) | 3 | 27% |
| Scientists | 1 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 142 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 142 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 16 | 11% |
| Researcher | 11 | 8% |
| Student > Master | 11 | 8% |
| Other | 5 | 4% |
| Student > Postgraduate | 5 | 4% |
| Other | 22 | 15% |
| Unknown | 72 | 51% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 15% |
| Biochemistry, Genetics and Molecular Biology | 15 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 6% |
| Nursing and Health Professions | 8 | 6% |
| Agricultural and Biological Sciences | 4 | 3% |
| Other | 12 | 8% |
| Unknown | 73 | 51% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 November 2020.
All research outputs
#6,448,566
of 25,387,668 outputs
Outputs from Breast Cancer Research
#737
of 2,054 outputs
Outputs of similar age
#133,751
of 440,859 outputs
Outputs of similar age from Breast Cancer Research
#14
of 32 outputs
Altmetric has tracked 25,387,668 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 2,054 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.2. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 440,859 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.